New Delhi, Jan 28 (UNI) Glenmark Pharmaceuticals today said the company has received the US Food and Drug Administration's (USFDA) approval for its semi-solid dosage manufacturing plant at Baddi in Himachal Pradesh.
The Baddi plant has also received Good Manufacturing Practice approval from UK nodal agency Modern Humanities Research Association and from therapeutic products directorate, Canada, Glenmark informed the Bombay Stock Exchange, the company said in a statement.
''The current GMP accreditation by USFDA for Baddi site is a significant milestone for Glenmark, since other plants of the company at Ankleshwar and Goa are already approved by these agencies'', said CEO and MD Glenn Saldanha.
These regulatory approvals in US and EU markets have opened huge opportunities for Glenmark. With this, the company envisages the launch of products in skin care segment, the statement added.
The company has its formulation manufacturing facilities in Goa, Nasik and Baddi in India and in Brazil and Czech Republic.
UNI AK RAR RS1405